Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. de Zeeuw D, et al. Among authors: cain va. Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4. Lancet Diabetes Endocrinol. 2015. PMID: 25660356 Clinical Trial.
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS. Ballantyne CM, et al. Among authors: cain va. Am Heart J. 2006 May;151(5):975.e1-9. doi: 10.1016/j.ahj.2005.12.013. Am Heart J. 2006. PMID: 16644314 Clinical Trial.
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Ballantyne CM, Hoogeveen RC, Raya JL, Cain VA, Palmer MK, Karlson BW; GRAVITY Study Investigators. Ballantyne CM, et al. Among authors: cain va. Atherosclerosis. 2014 Jan;232(1):86-93. doi: 10.1016/j.atherosclerosis.2013.10.022. Epub 2013 Nov 1. Atherosclerosis. 2014. PMID: 24401221 Clinical Trial.
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS. Ballantyne CM, et al. Among authors: cain va. Am J Cardiol. 2013 Feb 15;111(4):506-9. doi: 10.1016/j.amjcard.2012.10.037. Epub 2012 Dec 10. Am J Cardiol. 2013. PMID: 23237107 Clinical Trial.
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
Ballantyne CM, Raichlen JS, Cain VA. Ballantyne CM, et al. Among authors: cain va. J Am Coll Cardiol. 2008 Aug 19;52(8):626-32. doi: 10.1016/j.jacc.2008.04.052. J Am Coll Cardiol. 2008. PMID: 18702965 Free article. Clinical Trial.
51 results